Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has shared an update.
ImmuneOnco Biopharmaceuticals has announced the receipt of a $10 million milestone payment from Instil Bio, following FDA clearance to initiate a Phase I clinical trial for their bispecific antibody IMM2510/AXN-2510. This payment marks a significant step in the collaboration between the two companies, highlighting their commitment to advancing cancer therapies and potentially strengthening ImmuneOnco’s position in the biopharmaceutical industry.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. The company specializes in creating bispecific antibodies, such as IMM2510/AXN-2510, which target PD-L1 and VEGF for the treatment of multiple solid tumor cancers.
Average Trading Volume: 4,925,840
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.92B
For detailed information about 1541 stock, go to TipRanks’ Stock Analysis page.